emtricitabine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
nucleosides antiviral or antineoplastic agents, cytarabine or azacitidine derivatives 1003 143491-57-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • emtricitabine
  • coviracil
  • emtriva
A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.
  • Molecular weight: 247.24
  • Formula: C8H10FN3O3S
  • CLOGP: -1.29
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 88.15
  • ALOGS: -2.09
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.20 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 112 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 73 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 11.56 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

DateAgencyCompanyOrphan
Oct. 24, 2003 EMA
July 2, 2003 FDA GILEAD
March 23, 2005 PMDA Japan Tobacco Inc.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Abortion spontaneous 640.15 20.25 256 9524 41516 50553828
Exposure during pregnancy 485.10 20.25 297 9483 120718 50474626
Foetal exposure during pregnancy 412.76 20.25 166 9614 27193 50568151
Abortion induced 332.13 20.25 107 9673 9237 50586107
Immune reconstitution inflammatory syndrome 224.23 20.25 70 9710 5446 50589898
Stillbirth 223.11 20.25 71 9709 5881 50589463
Pregnancy 209.77 20.25 106 9674 29471 50565873
Premature baby 192.16 20.25 86 9694 18251 50577093
Virologic failure 190.61 20.25 47 9733 1517 50593827
Enlarged clitoris 170.27 20.25 29 9751 127 50595217
Viral mutation identified 163.93 20.25 42 9738 1587 50593757
Blood HIV RNA increased 162.34 20.25 34 9746 515 50594829
Drug interaction 154.30 20.25 191 9589 199430 50395914
Hyperandrogenism 151.13 20.25 25 9755 88 50595256
Viral load increased 107.36 20.25 28 9752 1135 50594209
Drug resistance 105.92 20.25 58 9722 18931 50576413
Premature labour 105.00 20.25 49 9731 11427 50583917
Pathogen resistance 101.35 20.25 39 9741 5650 50589694
Maternal exposure during pregnancy 95.59 20.25 135 9645 159643 50435701
Lipodystrophy acquired 89.74 20.25 25 9755 1304 50594040
CD4 lymphocytes decreased 89.56 20.25 25 9755 1314 50594030
Fanconi syndrome acquired 84.13 20.25 22 9758 901 50594443
Hydrops foetalis 82.85 20.25 18 9762 327 50595017
Cushing's syndrome 76.56 20.25 19 9761 629 50594715
Renal tubular disorder 74.80 20.25 25 9755 2412 50592932
Premature rupture of membranes 73.12 20.25 29 9751 4551 50590793
Spina bifida 70.26 20.25 18 9762 679 50594665
Hepatic cytolysis 69.20 20.25 33 9747 8070 50587274
Live birth 67.18 20.25 41 9739 16367 50578977
Pain 65.24 20.25 16 9764 578887 50016457
Hyperbilirubinaemia 63.99 20.25 33 9747 9537 50585807
Pre-eclampsia 60.40 20.25 30 9750 8014 50587330
Oligohydramnios 60.29 20.25 27 9753 5723 50589621
Drug ineffective 59.98 20.25 43 9737 819290 49776054
Autoimmune hepatitis 59.31 20.25 29 9751 7490 50587854
Acute kidney injury 58.38 20.25 133 9647 227925 50367419
Maternal drugs affecting foetus 56.96 20.25 25 9755 5052 50590292
Immune reconstitution inflammatory syndrome associated tuberculosis 56.12 20.25 13 9767 319 50595025
Premature delivery 53.57 20.25 41 9739 23622 50571722
Adrenal suppression 52.51 20.25 15 9765 857 50594487
Ultrasound antenatal screen abnormal 50.29 20.25 10 9770 115 50595229
CSF HIV escape syndrome 46.32 20.25 9 9771 91 50595253
Foetal death 45.63 20.25 25 9755 8155 50587189
Congenital anomaly 44.29 20.25 15 9765 1506 50593838
Caesarean section 44.23 20.25 31 9749 15608 50579736
Ventricular septal defect 42.44 20.25 19 9761 4022 50591322
HIV infection 42.11 20.25 10 9770 274 50595070
Melanoderma 41.71 20.25 9 9771 158 50595186
Rash maculo-papular 41.17 20.25 37 9743 26604 50568740
Hepatitis fulminant 40.66 20.25 17 9763 3051 50592293
Renal tubular necrosis 40.58 20.25 25 9755 10143 50585201
Osteonecrosis 40.29 20.25 34 9746 22483 50572861
Meningomyelocele 39.74 20.25 11 9769 560 50594784
Jaundice 39.46 20.25 36 9744 26393 50568951
Lipohypertrophy 38.97 20.25 11 9769 602 50594742
Oesophageal candidiasis 38.60 20.25 19 9761 4975 50590369
Hepatitis 37.78 20.25 38 9742 31415 50563929
Treatment noncompliance 37.27 20.25 37 9743 30113 50565231
Drug reaction with eosinophilia and systemic symptoms 37.22 20.25 36 9744 28388 50566956
Patent ductus arteriosus 37.08 20.25 17 9763 3803 50591541
Renal tubular acidosis 36.46 20.25 13 9767 1521 50593823
Foetal growth restriction 36.27 20.25 20 9760 6607 50588737
Fanconi syndrome 36.24 20.25 12 9768 1124 50594220
Renal colic 35.51 20.25 12 9768 1197 50594147
Congenital genital malformation female 35.46 20.25 6 9774 25 50595319
Renal failure 35.11 20.25 69 9711 106564 50488780
Ectopic pregnancy 34.59 20.25 14 9766 2313 50593031
Fall 34.38 20.25 11 9769 334921 50260423
Placenta praevia 34.26 20.25 11 9769 935 50594409
Sudden infant death syndrome 34.24 20.25 8 9772 204 50595140
Malaria 34.24 20.25 8 9772 204 50595140
Gestational diabetes 34.05 20.25 20 9760 7445 50587899
Fatigue 33.88 20.25 53 9727 707548 49887796
Adrenogenital syndrome 32.97 20.25 6 9774 41 50595303
Cholestasis 32.94 20.25 32 9748 25369 50569975
Hereditary optic atrophy 32.61 20.25 5 9775 9 50595335
Haemolytic anaemia 32.46 20.25 21 9759 9271 50586073
Congenital pulmonary valve disorder 32.14 20.25 6 9774 48 50595296
Congenital hydrocephalus 31.82 20.25 7 9773 135 50595209
Polydactyly 31.19 20.25 8 9772 303 50595041
Spinocerebellar disorder 30.83 20.25 5 9775 15 50595329
Ectopic kidney 30.58 20.25 6 9774 64 50595280
Hydrocephalus 30.54 20.25 16 9764 4772 50590572
Polyhydramnios 29.48 20.25 12 9768 2013 50593331
Peripheral swelling 29.11 20.25 3 9777 205933 50389411
Lactic acidosis 29.02 20.25 34 9746 33321 50562023
Anaemia 28.41 20.25 110 9670 252346 50342998
Eyelid oedema 27.31 20.25 19 9761 9447 50585897
Tubulointerstitial nephritis 27.28 20.25 23 9757 15188 50580156
HIV-associated neurocognitive disorder 26.84 20.25 6 9774 125 50595219
Glucocorticoids increased 26.79 20.25 6 9774 126 50595218
Dermatitis exfoliative 26.72 20.25 15 9765 5127 50590217
Porphyria non-acute 26.69 20.25 7 9773 290 50595054
Coarctation of the aorta 26.35 20.25 8 9772 565 50594779
Pregnancy on oral contraceptive 26.14 20.25 9 9771 949 50594395
Congenital genital malformation 25.99 20.25 6 9774 145 50595199
Neonatal respiratory arrest 25.78 20.25 5 9775 50 50595294
Cushingoid 25.65 20.25 16 9764 6629 50588715
Central obesity 25.57 20.25 9 9771 1013 50594331
Cloacal exstrophy 25.53 20.25 6 9774 157 50595187
Chronic papillomatous dermatitis 25.52 20.25 5 9775 53 50595291
Caudal regression syndrome 25.14 20.25 6 9774 168 50595176
Skin striae 25.04 20.25 9 9771 1077 50594267
Neural tube defect 24.55 20.25 6 9774 186 50595158
Hypophosphataemia 24.54 20.25 17 9763 8397 50586947
ACTH stimulation test abnormal 24.19 20.25 4 9776 14 50595330
Generalised anxiety disorder 23.83 20.25 10 9770 1810 50593534
Prurigo 23.78 20.25 8 9772 787 50594557
Transaminases increased 23.60 20.25 28 9752 27796 50567548
Neonatal respiratory distress syndrome 23.24 20.25 11 9769 2643 50592701
Abdominal discomfort 23.06 20.25 8 9772 231633 50363711
Foetal cardiac disorder 22.57 20.25 4 9776 23 50595321
Abortion infected 22.57 20.25 4 9776 23 50595321
Hepatotoxicity 22.44 20.25 27 9753 27199 50568145
Adrenal insufficiency 22.43 20.25 20 9760 14223 50581121
Thymus hypoplasia 22.43 20.25 4 9776 24 50595320
Blood phosphorus decreased 22.30 20.25 12 9768 3777 50591567
Nasopharyngitis 22.29 20.25 5 9775 192922 50402422
Umbilical cord abnormality 21.79 20.25 7 9773 596 50594748
Proteinuria 21.68 20.25 21 9759 16576 50578768
HIV test positive 21.65 20.25 4 9776 30 50595314
Pulmonary valve sclerosis 21.32 20.25 4 9776 33 50595311
Cholestasis of pregnancy 21.02 20.25 8 9772 1123 50594221
Pulmonary tuberculosis 20.95 20.25 12 9768 4261 50591083
CD4 lymphocytes increased 20.85 20.25 5 9775 143 50595201
Arthralgia 20.78 20.25 33 9747 438669 50156675
Retinal toxicity 20.64 20.25 8 9772 1180 50594164
Renal tubular dysfunction 20.60 20.25 6 9774 367 50594977
Nephropathy toxic 20.59 20.25 15 9765 8014 50587330
Bladder agenesis 20.59 20.25 5 9775 151 50595193
Genitalia external ambiguous 20.37 20.25 5 9775 158 50595186
Anal atresia 20.32 20.25 6 9774 385 50594959

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 776.77 14.00 261 18784 7541 29547941
Fanconi syndrome acquired 241.49 14.00 76 18969 1766 29553716
Blood HIV RNA increased 225.01 14.00 63 18982 961 29554521
Virologic failure 220.29 14.00 79 18966 2768 29552714
Drug interaction 186.49 14.00 399 18646 196986 29358496
Viral load increased 181.97 14.00 63 18982 1986 29553496
Viral mutation identified 173.71 14.00 64 18981 2424 29553058
Drug resistance 168.44 14.00 127 18918 21413 29534069
Renal tubular disorder 158.18 14.00 70 18975 4282 29551200
Pathogen resistance 143.64 14.00 80 18965 8036 29547446
Renal colic 141.18 14.00 49 18996 1556 29553926
Psychiatric decompensation 136.48 14.00 47 18998 1457 29554025
Genotype drug resistance test positive 120.85 14.00 39 19006 984 29554498
CD4 lymphocytes decreased 107.48 14.00 40 19005 1558 29553924
Depression suicidal 107.43 14.00 38 19007 1277 29554205
Tearfulness 102.94 14.00 39 19006 1597 29553885
Fanconi syndrome 89.49 14.00 35 19010 1563 29553919
Acute HIV infection 89.36 14.00 18 19027 54 29555428
Osteonecrosis 82.64 14.00 69 18976 13450 29542032
HIV-associated neurocognitive disorder 81.04 14.00 22 19023 297 29555185
Renal tubular necrosis 79.20 14.00 69 18976 14246 29541236
Jaundice 71.19 14.00 91 18954 29205 29526277
Paranoia 70.07 14.00 55 18990 9822 29545660
Acute kidney injury 68.43 14.00 344 18701 264923 29290559
Foetal exposure during pregnancy 68.23 14.00 96 18949 33771 29521711
Nephropathy toxic 68.03 14.00 56 18989 10700 29544782
Nephrolithiasis 66.83 14.00 82 18963 25252 29530230
Cytomegalovirus chorioretinitis 65.83 14.00 35 19010 3203 29552279
Proteinuria 65.78 14.00 65 18980 15739 29539743
Hepatic cytolysis 64.72 14.00 49 18996 8298 29547184
Death 63.96 14.00 76 18969 342008 29213474
Depressive symptom 63.61 14.00 28 19017 1689 29553793
Hypophosphataemia 60.29 14.00 46 18999 7878 29547604
Osteoporosis 59.75 14.00 52 18993 10717 29544765
Kaposi's sarcoma 59.52 14.00 22 19023 840 29554642
Lipodystrophy acquired 58.86 14.00 32 19013 3062 29552420
Acquired immunodeficiency syndrome 57.55 14.00 18 19027 409 29555073
Syphilis 56.92 14.00 17 19028 329 29555153
CSF HIV escape syndrome 52.78 14.00 14 19031 172 29555310
Psychomotor skills impaired 51.95 14.00 28 19017 2633 29552849
Renal failure 50.98 14.00 180 18865 118419 29437063
Glycosuria 49.78 14.00 21 19024 1141 29554341
Exposure during pregnancy 48.86 14.00 42 19003 8512 29546970
Hyperbilirubinaemia 48.84 14.00 54 18991 14880 29540602
Osteoporotic fracture 46.13 14.00 19 19026 972 29554510
Suicidal ideation 45.72 14.00 81 18964 34635 29520847
Vanishing bile duct syndrome 44.29 14.00 16 19029 572 29554910
Hepatitis B 42.01 14.00 32 19013 5465 29550017
Gene mutation 41.90 14.00 18 19027 1023 29554459
Renal tubular dysfunction 41.76 14.00 14 19031 399 29555083
Blood creatinine increased 41.68 14.00 135 18910 84967 29470515
Psychotic disorder 41.42 14.00 58 18987 20296 29535186
Portal hypertension 39.95 14.00 26 19019 3460 29552022
Osteomalacia 38.09 14.00 16 19029 860 29554622
HIV infection 36.59 14.00 17 19028 1164 29554318
Malignant neoplasm progression 36.33 14.00 3 19042 73856 29481626
Ocular icterus 36.23 14.00 22 19023 2593 29552889
Hepatitis C 35.87 14.00 36 19009 8874 29546608
Fall 35.59 14.00 37 19008 177141 29378341
Abnormal dreams 35.56 14.00 32 19013 6888 29548594
Cortisol decreased 35.54 14.00 15 19030 816 29554666
Anal cancer 35.47 14.00 12 19033 352 29555130
Congenital hearing disorder 35.35 14.00 9 19036 93 29555389
Meningitis cryptococcal 35.24 14.00 20 19025 2080 29553402
Lactic acidosis 32.86 14.00 65 18980 30182 29525300
Hepatitis 32.00 14.00 52 18993 20731 29534751
Mycobacterium avium complex infection 31.21 14.00 19 19026 2250 29553232
Hydrocele 31.17 14.00 18 19027 1935 29553547
Dyslipidaemia 31.09 14.00 28 19017 6033 29549449
Unmasking of previously unidentified disease 30.75 14.00 13 19032 710 29554772
Pulmonary tuberculosis 30.54 14.00 24 19021 4291 29551191
Depression 30.52 14.00 122 18923 85025 29470457
Anogenital warts 30.32 14.00 12 19033 553 29554929
Cachexia 29.98 14.00 28 19017 6321 29549161
Aspartate aminotransferase increased 29.45 14.00 95 18950 59630 29495852
Dyspnoea 28.04 14.00 112 18933 326620 29228862
Hypertriglyceridaemia 27.91 14.00 29 19016 7446 29548036
Disease progression 27.89 14.00 9 19036 81907 29473575
Peripheral swelling 27.77 14.00 4 19041 63735 29491747
Atrial fibrillation 27.53 14.00 17 19028 105629 29449853
CSF virus identified 27.36 14.00 6 19039 30 29555452
Drug abuse 26.80 14.00 9 19036 79874 29475608
Oesophageal candidiasis 26.50 14.00 21 19024 3800 29551682
Constipation 26.28 14.00 21 19024 114139 29441343
Product dose omission issue 25.82 14.00 15 19030 96368 29459114
Blood bilirubin increased 25.65 14.00 63 18982 33830 29521652
Hodgkin's disease 25.57 14.00 12 19033 840 29554642
Suicide attempt 25.39 14.00 63 18982 34047 29521435
Blood phosphorus decreased 25.31 14.00 18 19027 2767 29552715
Haemophilic arthropathy 25.10 14.00 7 19038 105 29555377
Mitochondrial myopathy 25.01 14.00 8 19037 196 29555286
Cytomegalovirus colitis 24.88 14.00 17 19028 2452 29553030
Hepatosplenomegaly 24.86 14.00 20 19025 3697 29551785
Pneumonia 24.85 14.00 114 18931 320058 29235424
Renal impairment 24.84 14.00 111 18934 81222 29474260
Burkitt's lymphoma 24.62 14.00 7 19038 113 29555369
Tubulointerstitial nephritis 24.30 14.00 42 19003 17601 29537881
Progressive multifocal leukoencephalopathy 24.24 14.00 29 19016 8690 29546792
Oral candidiasis 24.00 14.00 32 19013 10690 29544792
Hepatotoxicity 23.91 14.00 42 19003 17825 29537657
Blood alkaline phosphatase increased 23.87 14.00 55 18990 28351 29527131
Treatment noncompliance 23.87 14.00 50 18995 24177 29531305
Rash maculo-papular 23.78 14.00 50 18995 24239 29531243
Cardiac failure congestive 23.40 14.00 10 19035 76571 29478911
Liver function test abnormal 23.22 14.00 55 18990 28863 29526619
Hepatitis B DNA assay positive 23.06 14.00 6 19039 68 29555414
Alanine aminotransferase increased 22.55 14.00 98 18947 70846 29484636
Cerebral toxoplasmosis 22.46 14.00 13 19032 1403 29554079
Pancytopenia 22.09 14.00 109 18936 83059 29472423
Porphyria non-acute 22.00 14.00 9 19036 452 29555030
Hypotension 21.90 14.00 59 18986 194295 29361187
Lipoatrophy 21.49 14.00 9 19036 480 29555002
Atypical mycobacterial infection 21.43 14.00 10 19035 691 29554791
Stevens-Johnson syndrome 21.08 14.00 38 19007 16459 29539023
Supernumerary nipple 21.01 14.00 5 19040 38 29555444
Megakaryocytes increased 20.90 14.00 5 19040 39 29555443
Rhabdomyolysis 20.88 14.00 86 18959 60722 29494760
Product use issue 20.69 14.00 4 19041 51440 29504042
Lymphadenopathy 20.50 14.00 48 18997 25001 29530481
Rash 20.37 14.00 199 18846 189620 29365862
Hemiparaesthesia 20.36 14.00 5 19040 44 29555438
Cholestasis 20.35 14.00 46 18999 23416 29532066
Completed suicide 20.26 14.00 17 19028 90229 29465253
Acute hepatic failure 19.90 14.00 31 19014 11921 29543561
Psychomotor retardation 19.88 14.00 16 19029 2960 29552522
Anogenital dysplasia 19.63 14.00 6 19039 126 29555356
Blood pressure increased 19.04 14.00 12 19033 73791 29481691
Febrile neutropenia 18.75 14.00 27 19018 112213 29443269
Nodular regenerative hyperplasia 18.61 14.00 9 19036 674 29554808
Neonatal asphyxia 18.51 14.00 7 19038 285 29555197
Glucose urine present 18.33 14.00 10 19035 963 29554519
AIDS related complication 18.24 14.00 4 19041 20 29555462
Cushingoid 18.21 14.00 14 19031 2424 29553058
Multiple-drug resistance 18.03 14.00 17 19028 3883 29551599
Congenital anomaly 17.96 14.00 11 19034 1317 29554165
Trisomy 21 17.92 14.00 8 19037 499 29554983
Beta 2 microglobulin urine increased 17.69 14.00 5 19040 79 29555403
Premature baby 17.41 14.00 36 19009 17244 29538238
Influenza 17.40 14.00 3 19042 41878 29513604
Lymphoma 17.08 14.00 26 19019 9802 29545680
Pancreatitis acute 17.06 14.00 44 19001 24341 29531141
Polydactyly 16.85 14.00 10 19035 1130 29554352
End stage AIDS 16.74 14.00 4 19041 31 29555451
Pulmonary venous thrombosis 16.73 14.00 5 19040 97 29555385
Crystal nephropathy 16.70 14.00 7 19038 374 29555108
Prurigo 16.43 14.00 8 19037 608 29554874
Nasopharyngitis 16.38 14.00 9 19036 59656 29495826
Cushing's syndrome 16.36 14.00 7 19038 394 29555088
Fibrous histiocytoma 16.27 14.00 5 19040 107 29555375
Secondary syphilis 16.21 14.00 4 19041 36 29555446
Ergot poisoning 16.21 14.00 4 19041 36 29555446
Antiviral drug level above therapeutic 16.21 14.00 4 19041 36 29555446
White matter lesion 16.02 14.00 8 19037 642 29554840
Joint swelling 15.94 14.00 6 19039 49624 29505858
Oesophageal carcinoma 15.83 14.00 17 19028 4530 29550952
Eagle Barrett syndrome 15.75 14.00 3 19042 6 29555476
Back pain 15.74 14.00 26 19019 102258 29453224
Nasal septum deviation 15.73 14.00 9 19036 950 29554532
Gamma-glutamyltransferase increased 15.47 14.00 45 19000 26692 29528790
Anxiety 15.47 14.00 101 18944 85264 29470218
Haemodialysis 15.44 14.00 25 19020 9929 29545553
Adrenal atrophy 15.44 14.00 3 19042 7 29555475
Blood bilirubin decreased 15.32 14.00 6 19039 269 29555213
Lung transplant rejection 15.21 14.00 8 19037 716 29554766
Oxygen saturation decreased 15.17 14.00 5 19040 44932 29510550
Pain 15.14 14.00 58 18987 171374 29384108
Blood corticotrophin decreased 15.13 14.00 5 19040 136 29555346
Depressed mood 15.11 14.00 33 19012 16415 29539067
Varices oesophageal 15.09 14.00 14 19031 3132 29552350
Phosphorus metabolism disorder 14.89 14.00 3 19042 9 29555473
Cardio-respiratory arrest 14.84 14.00 7 19038 50594 29504888
Portal hypertensive gastropathy 14.68 14.00 7 19038 508 29554974
Pulmonary hilar enlargement 14.65 14.00 3 19042 10 29555472
Adrenogenital syndrome 14.47 14.00 4 19041 58 29555424
Drug ineffective 14.46 14.00 157 18888 363013 29192469
Seroconversion test positive 14.23 14.00 3 19042 12 29555470
Pulmonary oedema 14.01 14.00 5 19040 42730 29512752

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Immune reconstitution inflammatory syndrome 950.00 15.53 288 20375 12182 64465887
Abortion spontaneous 483.82 15.53 210 20453 24933 64453136
Viral mutation identified 368.55 15.53 103 20560 3243 64474826
Virologic failure 351.39 15.53 100 20563 3366 64474703
Drug interaction 323.82 15.53 482 20181 361601 64116468
Blood HIV RNA increased 310.26 15.53 76 20587 1408 64476661
Abortion induced 279.55 15.53 97 20566 6291 64471778
Exposure during pregnancy 276.56 15.53 216 20447 77459 64400610
Pathogen resistance 251.74 15.53 108 20555 12435 64465634
Drug resistance 247.72 15.53 149 20514 34953 64443116
Viral load increased 217.60 15.53 64 20599 2423 64475646
Fanconi syndrome acquired 184.50 15.53 56 20607 2365 64475704
Stillbirth 177.80 15.53 60 20603 3573 64474496
Renal tubular disorder 166.02 15.53 65 20598 5922 64472147
CD4 lymphocytes decreased 150.57 15.53 48 20615 2387 64475682
Psychiatric decompensation 145.93 15.53 47 20616 2416 64475653
Genotype drug resistance test positive 137.50 15.53 37 20626 1007 64477062
Depression suicidal 117.67 15.53 40 20623 2435 64475634
Renal colic 115.71 15.53 39 20624 2313 64475756
Fanconi syndrome 113.36 15.53 39 20624 2462 64475607
CSF HIV escape syndrome 106.69 15.53 24 20639 301 64477768
Lipodystrophy acquired 102.14 15.53 41 20622 3986 64474083
Nephropathy toxic 99.93 15.53 65 20598 17449 64460620
Acute kidney injury 98.90 15.53 342 20321 448898 64029171
Jaundice 98.17 15.53 98 20565 48414 64429655
Renal tubular necrosis 97.53 15.53 70 20593 22040 64456029
Pregnancy 96.52 15.53 68 20595 20797 64457272
Tearfulness 96.25 15.53 41 20622 4632 64473437
HIV-associated neurocognitive disorder 95.82 15.53 22 20641 304 64477765
Hyperbilirubinaemia 84.18 15.53 63 20600 21142 64456927
Acute HIV infection 83.27 15.53 15 20648 52 64478017
Paranoia 81.98 15.53 56 20607 16296 64461773
Osteonecrosis 76.30 15.53 67 20596 28162 64449907
Renal tubular dysfunction 70.05 15.53 20 20643 680 64477389
Proteinuria 69.38 15.53 63 20600 27660 64450409
Cushing's syndrome 68.21 15.53 21 20642 930 64477139
Psychomotor skills impaired 67.03 15.53 30 20633 3815 64474254
Treatment noncompliance 66.97 15.53 76 20587 43406 64434663
Cytomegalovirus chorioretinitis 62.99 15.53 31 20632 4881 64473188
Nephrolithiasis 61.66 15.53 73 20590 43610 64434459
Immune reconstitution inflammatory syndrome associated tuberculosis 59.41 15.53 18 20645 755 64477314
Hypophosphataemia 56.79 15.53 43 20620 14677 64463392
Depressive symptom 56.54 15.53 28 20635 4468 64473601
Maternal exposure during pregnancy 56.15 15.53 106 20557 95778 64382291
Psychotic disorder 55.92 15.53 62 20601 34516 64443553
Renal failure 54.27 15.53 154 20509 181534 64296535
Pain 53.74 15.53 59 20604 553452 63924617
Premature rupture of membranes 52.14 15.53 25 20638 3719 64474350
Gene mutation 52.12 15.53 21 20642 2061 64476008
Pulmonary tuberculosis 51.70 15.53 31 20632 7213 64470856
Oesophageal candidiasis 51.31 15.53 32 20631 7985 64470084
Joint swelling 50.98 15.53 5 20658 215377 64262692
Live birth 50.62 15.53 36 20627 11168 64466901
Fall 49.28 15.53 37 20626 416789 64061280
Cushingoid 47.78 15.53 30 20633 7573 64470496
Oligohydramnios 47.00 15.53 22 20641 3102 64474967
Adrenal suppression 46.14 15.53 17 20646 1310 64476759
Glycosuria 45.39 15.53 19 20644 2055 64476014
Hepatitis 45.23 15.53 64 20599 45518 64432551
Meningitis cryptococcal 44.68 15.53 21 20642 2988 64475081
Vanishing bile duct syndrome 43.08 15.53 16 20647 1261 64476808
Cortisol decreased 42.27 15.53 17 20646 1660 64476409
Abnormal dreams 41.61 15.53 31 20632 10325 64467744
Blood creatinine increased 41.41 15.53 116 20547 135666 64342403
Hepatic cytolysis 41.31 15.53 35 20628 14014 64464055
Rash maculo-papular 40.83 15.53 62 20601 46964 64431105
Renal impairment 40.83 15.53 115 20548 134902 64343167
Portal hypertension 40.24 15.53 25 20638 6194 64471875
Cholestasis 40.16 15.53 60 20603 44812 64433257
Drug reaction with eosinophilia and systemic symptoms 39.53 15.53 66 20597 54151 64423918
Tubulointerstitial nephritis 39.29 15.53 49 20614 30860 64447209
Lactic acidosis 38.58 15.53 70 20593 61340 64416729
Peripheral swelling 38.06 15.53 10 20653 209143 64268926
Hepatotoxicity 38.02 15.53 55 20608 39907 64438162
Premature labour 37.96 15.53 26 20637 7594 64470475
Autoimmune hepatitis 37.89 15.53 29 20634 10055 64468014
CSF virus identified 36.80 15.53 7 20656 35 64478034
Pancytopenia 36.62 15.53 115 20548 143194 64334875
Megakaryocytes increased 36.61 15.53 8 20655 87 64477982
Mycobacterium avium complex infection 36.53 15.53 20 20643 3920 64474149
Nasopharyngitis 36.40 15.53 9 20654 196064 64282005
Haemolytic anaemia 35.38 15.53 34 20629 16019 64462050
Completed suicide 35.07 15.53 14 20649 224400 64253669
Blood phosphorus decreased 34.57 15.53 22 20641 5683 64472386
Malaria 34.34 15.53 10 20653 365 64477704
Ocular icterus 34.28 15.53 21 20642 5077 64472992
Spina bifida 34.19 15.53 7 20656 54 64478015
Central obesity 34.10 15.53 14 20649 1441 64476628
Osteoporosis 33.08 15.53 53 20610 42027 64436042
Pre-eclampsia 32.80 15.53 22 20641 6209 64471860
Unmasking of previously unidentified disease 32.43 15.53 14 20649 1633 64476436
Placenta praevia 31.96 15.53 11 20652 695 64477374
Syphilis 31.95 15.53 10 20653 468 64477601
Ultrasound antenatal screen abnormal 31.88 15.53 6 20657 28 64478041
Death 31.79 15.53 67 20596 482638 63995431
Blood bilirubin increased 31.67 15.53 62 20601 57491 64420578
Foetal exposure during pregnancy 31.54 15.53 19 20644 4457 64473612
Aspartate aminotransferase increased 31.41 15.53 97 20566 119691 64358378
Kaposi's sarcoma 31.32 15.53 11 20652 738 64477331
Osteomalacia 31.30 15.53 13 20650 1378 64476691
Drug ineffective 29.51 15.53 154 20509 840093 63637976
Premature delivery 29.48 15.53 33 20630 18556 64459513
Foetal death 28.99 15.53 20 20643 5910 64472159
Suicidal ideation 28.83 15.53 65 20598 66477 64411592
Hepatomegaly 28.55 15.53 31 20632 16851 64461218
Lung transplant rejection 28.47 15.53 12 20651 1320 64476749
Arthropathy 28.11 15.53 3 20660 120964 64357105
Hepatitis fulminant 27.97 15.53 20 20643 6254 64471815
Cerebral toxoplasmosis 27.90 15.53 13 20650 1813 64476256
Mitochondrial myopathy 27.77 15.53 8 20655 281 64477788
Viraemia 27.68 15.53 14 20649 2335 64475734
Foetal cardiac disorder 27.61 15.53 5 20658 18 64478051
Adrenal insufficiency 27.55 15.53 35 20628 22452 64455617
Product dose omission issue 27.53 15.53 14 20649 194733 64283336
Renal tubular acidosis 27.28 15.53 15 20648 2964 64475105
Osteoporotic fracture 27.25 15.53 16 20647 3582 64474487
Hypertriglyceridaemia 27.12 15.53 25 20638 11180 64466889
Dyslipidaemia 27.12 15.53 23 20640 9219 64468850
Lipohypertrophy 27.00 15.53 10 20653 782 64477287
Polydipsia 26.98 15.53 19 20644 5802 64472267
Hepatitis B 26.34 15.53 21 20642 7724 64470345
Cytomegalovirus colitis 25.95 15.53 16 20647 3912 64474157
Melanoderma 25.95 15.53 8 20655 356 64477713
Malignant neoplasm progression 25.72 15.53 3 20660 112868 64365201
Blood corticotrophin decreased 25.59 15.53 8 20655 373 64477696
Hepatitis C 25.55 15.53 24 20639 10991 64467078
Blood alkaline phosphatase increased 25.53 15.53 56 20607 56223 64421846
White matter lesion 25.51 15.53 12 20651 1710 64476359
Pain in extremity 25.47 15.53 36 20627 303049 64175020
Injection site pain 25.29 15.53 3 20660 111405 64366664
Hereditary optic atrophy 25.24 15.53 5 20658 32 64478037
Retinal toxicity 25.19 15.53 11 20652 1319 64476750
Cachexia 25.14 15.53 22 20641 9195 64468874
Acquired immunodeficiency syndrome 25.14 15.53 7 20656 217 64477852
Oral candidiasis 25.13 15.53 34 20629 23178 64454891
Constipation 25.01 15.53 22 20641 229315 64248754
Progressive multifocal leukoencephalopathy 24.95 15.53 30 20633 18202 64459867
Rhabdomyolysis 24.71 15.53 75 20588 91651 64386418
Depression 24.58 15.53 120 20543 183171 64294898
Skin striae 24.43 15.53 11 20652 1419 64476650
Toxoplasmosis 24.31 15.53 13 20650 2431 64475638
Oxygen saturation decreased 24.05 15.53 3 20660 107173 64370896
Alanine aminotransferase increased 23.89 15.53 98 20565 138933 64339136
Glucocorticoids increased 23.77 15.53 6 20657 126 64477943
Pregnancy on oral contraceptive 23.61 15.53 9 20654 762 64477307
Anaemia 23.51 15.53 204 20459 378476 64099593
Pneumocystis jirovecii pneumonia 23.37 15.53 36 20627 27598 64450471
Red blood cell abnormality 22.92 15.53 8 20655 527 64477542
Multiple-drug resistance 22.91 15.53 18 20645 6484 64471585
Musculoskeletal stiffness 22.20 15.53 6 20657 123200 64354869
Psychomotor retardation 22.03 15.53 16 20647 5127 64472942
Abdominal discomfort 21.74 15.53 16 20647 182306 64295763
Aplasia pure red cell 21.71 15.53 18 20645 6996 64471073
Calculus urinary 21.69 15.53 11 20652 1846 64476223
Eyelid oedema 21.56 15.53 23 20640 12256 64465813
Hepatosplenomegaly 21.48 15.53 16 20647 5327 64472742
Fatigue 21.10 15.53 147 20516 748583 63729486
Arthralgia 21.06 15.53 72 20591 442188 64035881
Polyhydramnios 20.92 15.53 10 20653 1477 64476592
Oesophageal carcinoma 20.87 15.53 15 20648 4728 64473341
Dyspnoea 20.79 15.53 140 20523 718534 63759535
Blood pressure increased 20.75 15.53 15 20648 172537 64305532
Lymphadenopathy 20.66 15.53 46 20617 46640 64431429
Cardiac failure congestive 20.63 15.53 8 20655 130572 64347497
ACTH stimulation test abnormal 20.56 15.53 4 20659 23 64478046
Meningitis tuberculous 20.43 15.53 9 20654 1102 64476967
Atrial fibrillation 20.41 15.53 15 20648 171074 64306995
Contraindicated product administered 19.90 15.53 5 20658 107824 64370245
Anogenital dysplasia 19.86 15.53 5 20658 104 64477965
Pancreatitis acute 19.84 15.53 43 20620 42812 64435257
Contusion 19.70 15.53 6 20657 113959 64364110
Pulmonary venous thrombosis 19.68 15.53 5 20658 108 64477961
Anogenital warts 19.67 15.53 8 20655 804 64477265
Prurigo 19.64 15.53 9 20654 1208 64476861
Caesarean section 19.59 15.53 21 20642 11253 64466816
Burkitt's lymphoma 19.10 15.53 5 20658 122 64477947
Hemiparaesthesia 19.10 15.53 5 20658 122 64477947
Secondary syphilis 18.99 15.53 4 20659 36 64478033
Pyrexia 18.57 15.53 266 20397 558378 63919691
Generalised anxiety disorder 18.53 15.53 10 20653 1905 64476164
Gamma-glutamyltransferase increased 18.41 15.53 45 20618 48465 64429604
Lower respiratory tract infection 18.23 15.53 4 20659 94610 64383459
HIV infection 18.20 15.53 8 20655 974 64477095
Anal cancer 17.97 15.53 7 20656 628 64477441
Antiviral drug level above therapeutic 17.94 15.53 4 20659 48 64478021
Drug level increased 17.80 15.53 36 20627 34160 64443909
Polyuria 17.62 15.53 21 20642 12622 64465447
Nasal septum deviation 17.59 15.53 9 20654 1539 64476530
Bradycardia 17.46 15.53 8 20655 118211 64359858
Anembryonic gestation 17.34 15.53 6 20657 385 64477684
Mitochondrial cytopathy 17.31 15.53 6 20657 387 64477682
Maternal drugs affecting foetus 17.20 15.53 9 20654 1611 64476458
Sinusitis 17.14 15.53 13 20650 145915 64332154
Stomatitis 16.84 15.53 7 20656 109598 64368471
Hepatorenal syndrome 16.83 15.53 12 20651 3734 64474335
Hypotension 16.82 15.53 64 20599 380910 64097159
Nervous system disorder 16.69 15.53 28 20635 23050 64455019
Carbon dioxide decreased 16.66 15.53 11 20652 3024 64475045
Depressed mood 16.59 15.53 39 20624 40973 64437096
Face oedema 16.54 15.53 29 20634 24732 64453337
Transaminases increased 16.53 15.53 41 20622 44553 64433516
Haemorrhoids thrombosed 16.49 15.53 5 20658 210 64477859
Cerebellar ataxia 16.39 15.53 9 20654 1774 64476295
Suicide attempt 16.33 15.53 55 20608 70952 64407117
Skin lesion 16.20 15.53 36 20627 36446 64441623
Cellulitis 16.06 15.53 5 20658 93652 64384417
Pneumonia 15.66 15.53 110 20553 559466 63918603
Drug hypersensitivity 15.62 15.53 33 20630 237782 64240287

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AF09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleoside and nucleotide reverse transcriptase inhibitors
ATC J05AR03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR08 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR09 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR17 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR18 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR19 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR20 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
ATC J05AR22 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Antivirals for treatment of HIV infections, combinations
FDA CS M0015066 Nucleosides
FDA MoA N0000009947 Nucleoside Reverse Transcriptase Inhibitors
FDA EPC N0000175462 Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
MeSH PA D019380 Anti-HIV Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D044966 Anti-Retroviral Agents
MeSH PA D000998 Antiviral Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019384 Nucleic Acid Synthesis Inhibitors
MeSH PA D018894 Reverse Transcriptase Inhibitors
CHEBI has role CHEBI:36044 antiviral drugs
CHEBI has role CHEBI:53756 reverse transcriptase inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Human immunodeficiency virus infection indication 86406008 DOID:526
Coronavirus infection off-label use 186747009
Prevention of HIV Infection after Exposure off-label use
Osteomalacia contraindication 4598005 DOID:10573
Hypophosphatemia contraindication 4996001
Suicidal thoughts contraindication 6471006
Hypercholesterolemia contraindication 13644009
Torsades de pointes contraindication 31722008
Depressive disorder contraindication 35489007
Fanconi syndrome contraindication 40488004 DOID:1062
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Aggressive behavior contraindication 61372001
Chronic type B viral hepatitis contraindication 61977001
Kidney disease contraindication 90708001 DOID:557
Lactic acidosis contraindication 91273001 DOID:3650
Prolonged QT interval contraindication 111975006
Chronic hepatitis C contraindication 128302006
Seizure disorder contraindication 128613002
Liver function tests abnormal contraindication 166603001
Paranoid disorder contraindication 191667009
Steatosis of liver contraindication 197321007
Mania contraindication 231494001
Disease of liver contraindication 235856003 DOID:409
Pathological fracture contraindication 268029009
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Severe depression contraindication 310497006
Osteopenia contraindication 312894000
Breastfeeding (mother) contraindication 413712001
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.95 acidic
pKa2 2.57 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV-1 INFECTION
200MG;EQ 25MG BASE;EQ 25MG BASE ODEFSEY GILEAD SCIENCES INC N208351 March 1, 2016 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV INFECTION
EQ 30MG BASE;120MG;EQ 15MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Oct. 7, 2021 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV INFECTION
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV INFECTION
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 7803788 Feb. 2, 2022 TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
200MG;300MG TRUVADA GILEAD N021752 Aug. 2, 2004 RX TABLET ORAL 8592397 Jan. 13, 2024 METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
200MG;300MG TRUVADA GILEAD N021752 Aug. 2, 2004 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV
200MG;300MG TRUVADA GILEAD N021752 Aug. 2, 2004 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
200MG;300MG TRUVADA GILEAD N021752 Aug. 2, 2004 RX TABLET ORAL 8716264 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;300MG TRUVADA GILEAD N021752 Aug. 2, 2004 RX TABLET ORAL 9457036 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;300MG TRUVADA GILEAD N021752 Aug. 2, 2004 RX TABLET ORAL 9744181 Jan. 13, 2024 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 8716264 Jan. 13, 2024 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9457036 Jan. 13, 2024 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9744181 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;300MG COMPLERA GILEAD SCIENCES INC N202123 Aug. 10, 2011 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;300MG COMPLERA GILEAD SCIENCES INC N202123 Aug. 10, 2011 RX TABLET ORAL 8716264 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;300MG COMPLERA GILEAD SCIENCES INC N202123 Aug. 10, 2011 RX TABLET ORAL 9457036 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;300MG COMPLERA GILEAD SCIENCES INC N202123 Aug. 10, 2011 RX TABLET ORAL 9744181 Jan. 13, 2024 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 8592397 Jan. 13, 2024 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 8716264 Jan. 13, 2024 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 9457036 Jan. 13, 2024 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 9744181 Jan. 13, 2024 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;300MG COMPLERA GILEAD SCIENCES INC N202123 Aug. 10, 2011 RX TABLET ORAL 7125879 April 21, 2025 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;EQ 25MG BASE ODEFSEY GILEAD SCIENCES INC N208351 March 1, 2016 RX TABLET ORAL 7125879 April 21, 2025 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;300MG COMPLERA GILEAD SCIENCES INC N202123 Aug. 10, 2011 RX TABLET ORAL 8841310 Dec. 9, 2025 TREATMENT OF HIV INFECTION
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9018192 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9018192 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9545414 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN ADULTS
600MG;200MG;300MG ATRIPLA GILEAD SCIENCES N021937 July 12, 2006 RX TABLET ORAL 9545414 June 13, 2026 TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 7176220 Aug. 27, 2026 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 7176220 Aug. 27, 2026 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 7635704 Oct. 26, 2026 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 7635704 Oct. 26, 2026 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 9891239 Sept. 3, 2029 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 9891239 Sept. 3, 2029 TREATMENT OF HIV INFECTION
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8148374 Sept. 3, 2029 TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8148374 Sept. 3, 2029 TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8148374 Sept. 3, 2029 TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
150MG;150MG;200MG;300MG STRIBILD GILEAD SCIENCES INC N203100 Aug. 27, 2012 RX TABLET ORAL 8633219 April 30, 2030 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 8633219 April 30, 2030 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV INFECTION
150MG;150MG;200MG;EQ 10MG BASE GENVOYA GILEAD SCIENCES INC N207561 Nov. 5, 2015 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV INFECTION
120MG;EQ 15MG BASE DESCOVY GILEAD SCIENCES INC N208215 Jan. 7, 2022 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION
120MG;EQ 15MG BASE DESCOVY GILEAD SCIENCES INC N208215 Jan. 7, 2022 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 8754065 Aug. 15, 2032 PROPHYLAXIS OF HIV-1 INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 9296769 Aug. 15, 2032 PROPHYLAXIS OF HIV-1 INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;EQ 25MG BASE ODEFSEY GILEAD SCIENCES INC N208351 March 1, 2016 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV INFECTION
200MG;EQ 25MG BASE;EQ 25MG BASE ODEFSEY GILEAD SCIENCES INC N208351 March 1, 2016 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV INFECTION
EQ 30MG BASE;120MG;EQ 15MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Oct. 7, 2021 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV INFECTION
EQ 30MG BASE;120MG;EQ 15MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Oct. 7, 2021 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV INFECTION
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV INFECTION
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV INFECTION
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 8754065 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 9296769 Aug. 15, 2032 TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS
EQ 30MG BASE;120MG;EQ 15MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Oct. 7, 2021 RX TABLET ORAL 10385067 June 19, 2035 TREATMENT OF HIV INFECTION
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL 10385067 June 19, 2035 TREATMENT OF HIV INFECTION
150MG;800MG;200MG;EQ 10MG BASE SYMTUZA JANSSEN PRODS N210455 July 17, 2018 RX TABLET ORAL 10786518 July 19, 2038 TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH <50 COPIES/ML HIV-1 RNA AFTER >= 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL June 18, 2022 NEW PATIENT POPULATION
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL Oct. 3, 2022 FOR USE IN AT RISK ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF HIV-1 INFECTION FROM SEXUAL ACQUISITION, EXCLUDING INDIVIDUALS AT RISK FROM RECEPTIVE VAGINAL SEX
EQ 30MG BASE;120MG;EQ 15MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Oct. 7, 2021 RX TABLET ORAL Feb. 7, 2023 NEW CHEMICAL ENTITY
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL Feb. 7, 2023 NEW CHEMICAL ENTITY
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL Feb. 24, 2024 LABELING REVISIONS RELATED TO CLINICAL STUDIES
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL Sept. 28, 2024 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 35KG
200MG;EQ 25MG BASE DESCOVY GILEAD SCIENCES INC N208215 April 4, 2016 RX TABLET ORAL Sept. 28, 2024 IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS OTHER THAN PROTEASE INHIBITORS THAT REQUIRE A CYP3A INHIBITOR, FOR THE TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS UNDER 12 YEARS OF AGE WEIGHING AT LEAST 25KG AND LESS THAN 35KG
EQ 50MG BASE;200MG;EQ 25MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Feb. 7, 2018 RX TABLET ORAL June 18, 2026 FOR HIV-1 INFECTION IN PEDIATRIC PTS AT LEAST 25 KG W/ NO ANTIRETROVIRAL (ARV) TX HX OR TO REPLACE CURRENT ARV REGIMEN FOR VIROLOGICALLY-SUPPRESSED ON STABLE ARV W/ NO HX TX FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED W/ RESISTANCE TO BIC, FTC, OR TAF
EQ 30MG BASE;120MG;EQ 15MG BASE BIKTARVY GILEAD SCIENCES INC N210251 Oct. 7, 2021 RX TABLET ORAL Oct. 7, 2028 A COMPLETE REGIMEN FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN PEDIATRIC PATIENTS WEIGHING 14 KG TO LESS THAN 25 KG WHO HAVE NO ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY-SUPPRESSED (HIV-1 RNA LESS THAN 50 COPIES PER ML) ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF BIKTARVY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Reverse transcriptase/RNaseH Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4021395 VUID
N0000148813 NUI
D01199 KEGG_DRUG
4021395 VANDF
C0909839 UMLSCUI
CHEBI:31536 CHEBI
ETV PDB_CHEM_ID
CHEMBL885 ChEMBL_ID
DB00879 DRUGBANK_ID
D000068679 MESH_DESCRIPTOR_UI
60877 PUBCHEM_CID
11244 IUPHAR_LIGAND_ID
7822 INN_ID
G70B4ETF4S UNII
276237 RXNORM
17421 MMSL
338322 MMSL
47041 MMSL
d04884 MMSL
001321 NDDF
404855005 SNOMEDCT_US
404856006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 3 0093-5234 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 0093-7607 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 0093-7704 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 0378-1930 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 0904-7172 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 15584-0101 TABLET, FILM COATED 200 mg ORAL NDA 34 sections
Emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 2 16714-534 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Emtricitabine and tenofovir disoproxil fumarate HUMAN PRESCRIPTION DRUG LABEL 2 31722-560 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
Emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 2 33342-106 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 3 33342-138 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 42291-439 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
Efavirenz, emtricitabine and tenofovir disoproxil fumarate Human Prescription Drug Label 3 42385-915 TABLET, FILM COATED 200 mg ORAL ANDA 30 sections
Emtricitabine and Tenofovir Disoproxil Fumarate Human Prescription Drug Label 2 42385-953 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 42543-719 TABLET 200 mg ORAL ANDA 27 sections
Emtriva HUMAN PRESCRIPTION DRUG LABEL 1 46014-0601 CAPSULE 200 mg ORAL NDA 29 sections
Truvada HUMAN PRESCRIPTION DRUG LABEL 2 50090-0870 TABLET, FILM COATED 200 mg ORAL NDA 33 sections
Truvada HUMAN PRESCRIPTION DRUG LABEL 2 50090-0870 TABLET, FILM COATED 200 mg ORAL NDA 33 sections
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE HUMAN PRESCRIPTION DRUG LABEL 2 50090-5957 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
Emtricitabine and Tenofovir Disoproxil Fumarate HUMAN PRESCRIPTION DRUG LABEL 2 51407-112 TABLET 200 mg ORAL ANDA 27 sections
Truvada HUMAN PRESCRIPTION DRUG LABEL 2 52959-969 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 53808-0208 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
Emtriva HUMAN PRESCRIPTION DRUG LABEL 1 53808-0801 CAPSULE 200 mg ORAL NDA 29 sections
Truvada HUMAN PRESCRIPTION DRUG LABEL 2 53808-0805 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
Stribild HUMAN PRESCRIPTION DRUG LABEL 4 53808-0887 TABLET, FILM COATED 200 mg ORAL NDA 30 sections
Emtriva HUMAN PRESCRIPTION DRUG LABEL 1 54868-4853 CAPSULE 200 mg ORAL NDA 30 sections
Truvada HUMAN PRESCRIPTION DRUG LABEL 2 54868-5141 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
Atripla HUMAN PRESCRIPTION DRUG LABEL 3 54868-5643 TABLET, FILM COATED 200 mg ORAL NDA 31 sections
COMPLERA HUMAN PRESCRIPTION DRUG LABEL 3 54868-6360 TABLET, FILM COATED 200 mg ORAL NDA 32 sections
Symtuza HUMAN PRESCRIPTION DRUG LABEL 4 59676-800 TABLET, FILM COATED 200 mg ORAL NDA 34 sections
Symtuza HUMAN PRESCRIPTION DRUG LABEL 4 59676-800 TABLET, FILM COATED 200 mg ORAL NDA 34 sections